Form 4: Cutera Director Lewin Receives Option Repricing

Nicholas Sheridan Lewin, a director at Cutera, Inc., had stock options repriced to $1.54 per share on July 15, 2024.

Summary

• On July 15, 2024, Nicholas Sheridan Lewin, a director at Cutera, Inc., had his stock options repriced.
• The exercise price of the options was adjusted to $1.54 per share.
• The repricing was approved by Cutera's Board of Directors.
• Lewin was granted 25,327 options at the new price.
• One-third of the shares subject to the option vested on May 19, 2024, with the remainder vesting in equal annual installments thereafter, contingent upon continued service.

Sentiment

Score: 5

Explanation: The document itself is neutral, simply reporting a transaction. The impact on the company is dependent on whether the repricing motivates the director to improve performance.

Positives

• The option repricing may incentivize the director to improve company performance.

Industry Context

Option repricing is a tool companies use to re-incentivize employees or directors when the stock price has fallen significantly below the original option exercise price. It is common in the tech and biotech industries.

Comparison to Industry Standards

• Option repricing is a fairly common practice, especially in volatile sectors like biotechnology, where Cutera operates.
• Companies like Novavax and Inovio Pharmaceuticals have also used option repricing to retain and motivate key personnel during periods of stock price decline.

Stakeholder Impact

• Shareholders may view the repricing as a positive if it leads to improved company performance.
• The director is incentivized to increase shareholder value.

Key Dates

Keywords

Cutera, Lewin, Option Repricing, Director, Stock Options, CUTR